S-1: Ekso Bionics Announces Public Offering of Common Stock and Pre-Funded Warrants

Ekso Bionics is launching a public offering of common stock and pre-funded warrants to raise capital for general corporate purposes, including expansion and R&D.

Summary

• Ekso Bionics Holdings, Inc. has filed a registration statement for a proposed public offering.
• The offering includes shares of common stock and pre-funded warrants to purchase common stock.
• Pre-funded warrants are offered to investors whose purchase of common stock would result in exceeding a beneficial ownership threshold (4.99% or 9.99%).
• The purchase price of each pre-funded warrant will be the price per share minus $0.001, with an exercise price of $0.001 per share.
• The offering is underwritten by Craig-Hallum Capital Group LLC, acting as the sole book-running manager.
• Ekso Bionics intends to use the net proceeds for general corporate purposes, including growth of the EksoHealth segment, research and development, and potential acquisitions.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol EKSO.
• The underwriter has a 30-day option to purchase additional shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The announcement is a standard capital raising activity. While the company highlights growth opportunities, it also acknowledges the risks associated with its business.

Positives

• The offering aims to raise capital for growth and expansion, particularly in the EksoHealth segment.
• Medicare CMS reimbursement of the Ekso Indego Personal device may increase revenue.
• The company is pursuing strategic initiatives, including potential acquisitions.

Negatives

• Investing in the company's securities involves a high degree of risk.
• The company has incurred significant losses to date and anticipates continuing to incur losses in the future, and we may not achieve or maintain profitability.
• The markets in which our products are sold are highly competitive and continue to develop.

Risks

• The markets in which our products are sold are highly competitive and continue to develop.
• We may not be able to reduce the cost to manufacture or service our products as planned.
• If we or our third-party manufacturers are unable to produce our products at a satisfactory quality, in a timely manner, in sufficient quantities or at an acceptable cost, our business could be negatively impacted.
• Shortages in the materials used to manufacture our products, as well as reductions in manufacturer capacity, could impact our future results.
• Coverage policies and reimbursement levels of third-party payers, including Medicare or Medicaid, may impact sales of our products.
• The acquisition and integration of other companies, businesses, or technologies could result in operating difficulties, dilution, and other harmful consequences.
• We may not be able to enhance our product offerings through our research and development efforts.
• We have incurred significant losses to date and anticipate continuing to incur losses in the future, and we may not achieve or maintain profitability.
• Our loan agreement with Pacific Western Bank imposes certain financial, and operational restrictions on us, limiting the discretion of our management in operating our business.
• Protecting our intellectual proprietary rights can be costly, and our success in doing so is not certain.
• If we fail to obtain or maintain necessary regulatory clearances or approvals for our medical device products, or if clearances or approvals for future products or modifications to existing products are delayed or not issued, our commercial operations would be harmed.
• Modifications to our EksoNR, Ekso Indego Therapy, Ekso Indego Personal, and our future products may require new 510(k) clearances or premarket approvals, or may require us to cease marketing or recall the modified products until clearances are obtained.
• Our failure to meet strict post-market regulatory requirements with respect to our products could require us to pay fines, incur other costs or even close our facilities.
• Our success depends on our management team, and on our ability to hire, train, retain, and motivate employees.

Future Outlook

The company intends to use the net proceeds from this offering for general corporate purposes, which may include growth and expansion of our EksoHealth segment as we work to increase our revenue following the establishment of Medicare CMS reimbursement of the Ekso Indego Personal device, research and development activities, selling, general and administrative costs, and pursuing strategic initiatives, which initiatives may include potential synergistic and accretive acquisitions, as well as meeting our other working capital needs.

Industry Context

This announcement reflects a company in the medical device sector seeking capital to expand its market presence and invest in future growth, a common strategy in this industry.

Comparison to Industry Standards

• It is difficult to compare Ekso Bionics directly to industry standards without specific financial benchmarks for exoskeleton companies.
• However, similar companies in the rehabilitation robotics space, such as ReWalk Robotics and Myomo, also rely on capital markets to fund their operations and growth initiatives.
• The success of Ekso Bionics will depend on its ability to effectively commercialize its products and secure favorable reimbursement policies from healthcare providers, similar to the challenges faced by its competitors.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Employees may benefit from the company's growth and expansion plans.
• Customers may see improved products and services as a result of increased R&D.
• Suppliers may benefit from increased demand for materials and components.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company will proceed with the public offering, subject to market conditions and regulatory approvals.
• The underwriter will market the securities to potential investors.
• The company will use the net proceeds for the stated corporate purposes.

Key Dates

Keywords

public offering, common stock, pre-funded warrants, Ekso Bionics, EKSO, capital raise, exoskeleton, EksoHealth, Craig-Hallum, Medicare, reimbursement, research and development, acquisitions